Zobrazeno 1 - 10
of 78
pro vyhledávání: '"Chikashi, Yoshida"'
Autor:
Shinichi Ogawa, Tatsuhiro Sakamoto, Ryota Matsuoka, Kantaro Ishitsuka, Yasuko Ogino, Ayano Sootome, Kenichi Makishima, Chikashi Yoshida, Yufu Ito, Seiichi Shimizu, Takuya Suyama, Atsushi Shinagawa, Takayoshi Ito, Naoshi Obara, Manabu Kusakabe, Mamiko Sakata‐Yanagimoto, Yasushi Miyazaki, Yasuhito Nannya, Shigeru Chiba
Publikováno v:
Cancer Reports, Vol 7, Iss 1, Pp n/a-n/a (2024)
Abstract Background Hypomethylating agents, including azacytidine (AZA), are standard therapeutics for patients with high‐risk myelodysplastic syndromes (MDS), a group of myeloid neoplasms. However, treatment schedules are not unified in real‐wor
Externí odkaz:
https://doaj.org/article/f09fa49297404012bf6c2f22d92a991c
Publikováno v:
Journal of Epidemiology, Vol 32, Iss 1, Pp 27-33 (2022)
Background: The number of new noncommercial clinical studies conducted in Japan declined within the first year of the implementation of the Clinical Trials Act (CTA) on April 1, 2018. This study aimed to examine the impact of the CTA’s enforcement
Externí odkaz:
https://doaj.org/article/a666b8d683f14729ac698f3dd760db72
Autor:
Chisa Nakata, Akemi Itaya, Yuta Inomata, Hirokazu Yamaguchi, Chikashi Yoshida, Masahiko Nakazawa
Publikováno v:
International Journal of Forest Engineering. 34:64-75
Autor:
Noboru Asada, Jun Ando, Satoru Takada, Chikashi Yoshida, Kensuke Usuki, Atsushi Shinagawa, Kenichi Ishizawa, Toshihiro Miyamoto, Hiroatsu Iida, Nobuaki Dobashi, Sumiko Okubo, Hideyuki Honda, Tomomi Soshin, Yasuko Nishimura, Atsuko Tsutsui, Harumi Mukai, Kazuhito Yamamoto
Publikováno v:
Japanese Journal of Clinical Oncology.
Background In a Phase 3 international clinical trial (VIALE-C), venetoclax plus low-dose cytarabine improved the response rate and overall survival versus placebo plus low-dose cytarabine in patients with newly diagnosed acute myeloid leukemia who we
Autor:
Yoshiaki Abe, Mamiko Sakata-Yanagimoto, Manabu Fujisawa, Hiroaki Miyoshi, Yasuhito Suehara, Keiichiro Hattori, Manabu Kusakabe, Tatsuhiro Sakamoto, Hidekazu Nishikii, Tran B. Nguyen, Yohei Owada, Tsuyoshi Enomoto, Aya Sawa, Hiroko Bando, Chikashi Yoshida, Rikako Tabata, Toshiki Terao, Masahiro Nakayama, Koichi Ohshima, Kensuke Usuki, Tatsuya Oda, Kosei Matsue, Shigeru Chiba
Publikováno v:
Nature Cell Biology. 24:565-578
The activities of non-haematopoietic cells (NHCs), including mesenchymal stromal cells and endothelial cells, in lymphomas are reported to underlie lymphomagenesis. However, our understanding of lymphoma NHCs has been hampered by unexplained NHC hete
Publikováno v:
Journal of Epidemiology, Vol 32, Iss 1, Pp 27-33 (2022)
BackgroundThe number of new noncommercial clinical studies conducted in Japan declined within the first year of the implementation of the Clinical Trials Act (CTA) on April 1, 2018. This study aimed to examine the impact of the CTA’s enforcement on
Autor:
Yukiko Miura, Masanori Seki, Yuya Kamura, Takuya Komeno, Yukinori Inadome, Chikashi Yoshida, Haruo Ohtani, Ikuyo Tsutsumi
Publikováno v:
Internal Medicine
Hodgkin lymphoma (HL) is a hematologic malignancy that typically presents with lymphadenopathy. We herein report a patient with HL who presented with an intramuscular mass that required differentiation from an inflammatory lesion. A 65-year-old Japan
Autor:
Naoki, Kurita, Takayasu, Kato, Toru, Nanmoku, Yumiko, Maruyama, Yasuhito, Suehara, Keiichiro, Hattori, Tatsuhiro, Sakamoto, Yasuhisa, Yokoyama, Chikashi, Yoshida, Yuri, Tsuboi, Naoshi, Obara, Hidekazu, Nishikii, Mamiko, Sakata-Yanagimoto, Shigeru, Chiba
Publikováno v:
[Rinsho ketsueki] The Japanese journal of clinical hematology. 63(10)
NUP98::DDX10 is a rare fusion gene associated with acute myeloid leukemia (AML), for which the prognosis and indication for allogeneic hematopoietic stem cell transplantation are unknown. A 48-year-old woman was diagnosed with AML harboring NUP98::DD
Autor:
Qi Jiang, Kenichi Ishizawa, Satoru Takada, Wellington Luiz Mendes, Toshihiro Miyamoto, Takahiro Yamauchi, Nobuaki Dobashi, M. Kurokawa, Junya Kuroda, Chikashi Yoshida, Sumiko Okubo, Kensuke Usuki, Itaru Matsumura, Norio Komatsu, Andrew H. Wei, Hideyuki Honda, Norio Asou, Hiroatsu Iida, Satoshi Ichikawa, Yasushi Miyazaki
Publikováno v:
Japanese Journal of Clinical Oncology
Background In a multinational phase 3 trial (VIALE-C), venetoclax plus low-dose cytarabine prolonged overall survival vs placebo plus low-dose cytarabine in patients with newly diagnosed acute myeloid leukaemia ineligible for intensive chemotherapy,
Autor:
Chikashi Yoshida, Takeshi Kondo, Tomoki Ito, Masahiro Kizaki, Kazuhiko Yamamoto, Toshihiro Miyamoto, Yasuyoshi Morita, Tetsuya Eto, Yuna Katsuoka, Naoki Takezako, Nobuhiko Uoshima, Kazunori Imada, Jun Ando, Takuya Komeno, Akio Mori, Yuichi Ishikawa, Atsushi Satake, Junichi Watanabe, Yoshiko Kawakami, Tetsuo Morita, Ikue Taneike, Masahiko Nakayama, Yinghui Duan, Belen Garbayo Guijarro, Alexander Delgado, Cynthia Llamas, Hitoshi Kiyoi
Publikováno v:
International journal of hematology. 116(1)
Acute myeloid leukemia (AML) predominantly affects elderly adults, and its prognosis worsens with age. Treatment options for patients in Japan ineligible for intensive chemotherapy include cytarabine/aclarubicin ± granulocyte colony-stimulating fact